Pediatrics in Review
HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


(Pediatrics in Review. 2009;30:47-56. doi:10.1542/10.1542/pir.30-2-47)
© 2009 American Academy of Pediatrics


Click here for Adolescent Immunizations Correction Data Supplement
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Take the CME quiz:
Vol. 30 No. 2, February 2009
Right arrow Correction
Right arrow A correction has been published
Right arrow Rapid Responses: Submit a response
Right arrow Rapid Responses: View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Rapid Responses are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brigham, K. S.
Right arrow Articles by Goldstein, M. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brigham, K. S.
Right arrow Articles by Goldstein, M. A.
Related Collections
Right arrow Adolescent Medicine/Gynecology
Right arrow Infectious Diseases
Right arrow Preventive Pediatrics
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Adolescent Immunizations


Kathryn S. Brigham, MD*
Mark A. Goldstein, MD{dagger}
* Chief Resident, Massachusetts General Hospital for Children, Boston, Mass
{dagger} Editorial Board

Abbreviations: AAP: American Academy of Pediatrics • ACIP: Advisory Committee on Immunization Practices • CIN: cervical intraepithelial neoplasia • DTP: diphtheria toxoid, tetanus toxoid, and whole-cell pertussis • DTaP: diphtheria toxoid, tetanus toxoid, and acellular pertussis • FDA: United States Food and Drug Administration • GBS: Guillain Barré syndrome • HAV: hepatitis A virus • HBsAg: hepatitis B surface antigen • HBV: hepatitis B virus • HPV: human papillomavirus • IPV: inactivated poliovirus vaccine • LAIV: live-attenuated influenza vaccine • MCV4: tetravalent meningococcal conjugate vaccine • MPSV4: tetravalent meningococcal polysaccharide vaccine • OPV: oral poliovirus vaccine • PCV7: 7-valent pneumococcal conjugate vaccine • PPV23: 23-valent pneumococcal polysaccharide vaccine • Td: tetanus toxoid and reduced diphtheria toxoid • Tdap: tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis • TIV: trivalent inactivated influenza vaccine • VAERS: Vaccine Adverse Events Reporting System

The first 300 words of the full text of this article appear below.


    Objectives
 
After completing this article, readers should be able to:

  1. Discuss the rationale for the recent additions to the adolescent vaccination schedule.
  2. Describe the indications for vaccines in adolescents.


    Introduction
 
In the past 5 years, the immunization schedule for adolescents has undergone numerous changes. Several new vaccines have been licensed for use in adolescents. The human papillomavirus (HPV) vaccine is expected to decrease the incidence of genital warts, abnormal cervical cytology, and cervical cancer, thereby reducing significant medical, psychological, and economic burdens for patients and society. A new vaccine against meningococcal disease aims to lower the incidence of that rare infection and its associated significant mortality and morbidity. Although diphtheria and tetanus are very rare occurrences in adolescents, the incidence of pertussis has been increasing in this age group. Fortunately, two new vaccines against pertussis for adolescents should lower the incidence of that illness in this population as well as help to reduce pertussis in the high-risk infant and elderly populations. Finally, although influenza generally is a mild illness in adolescents, new recommendations to immunize all adolescents with an influenza vaccine has the objective of reducing the incidence of the disease and its associated morbidity and mortality in high-risk populations. In addition, for some older vaccines, indications and dosing recommendations have been modified.

Clinicians who provide care for adolescents should be knowledgeable about immunization recommendations because immunizing adolescents with age-appropriate vaccines reduces their disease burden. The recommendations for vaccines in individuals who are immunocompromised are beyond the scope of this article. The FigureGo shows the current adolescent immunization schedule. Contraindications for vaccines are listed in Table 1, and some adverse effects of vaccines are listed in Table 2.


Figure Removed (Available Only in the Full Text)
View larger version (53K):



 
Figure. Centers for Disease Control and Prevention 2008 adolescent immunization schedule. Available at http://www.cdc.gov/vaccines/recs/schedules/child-schedule.htm#printable.


Table 1. Contraindications to Vaccines*

Vaccine Contraindication

Human papillomavirus (HPV)
  • History of hypersensitivity to yeast
Tetravalent meningococcal conjugate vaccine (MCV4)
  • History of severe allergic reaction to diphtheria toxoid or to dry natural rubber latex
  • History of group B Streptococcus (GBS) is a relative contraindication; therefore, clinicians should discuss this with patients prior to administration
Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap)
  • History of encephalopathy within 7 days of administration of prior dose of pertussis vaccine not attributable to another cause
  • Boostrix® (GlaxoSmithKline Biologicals) should not be given if there is a history of anaphylaxis to latex because the tip and plunger of the needleless syringe contain latex
  • Adacel® (Sanofi Pasteur, Inc) preparations have no latex
Trivalent inactivated influenza vaccine (TIV)
  • History of anaphylaxis to eggs
Live-attenuated influenza vaccine (LAIV)
  • History of anaphylaxis to eggs
  • Chronic conditions that put the individual at higher risk for complications from influenza (eg, asthma, chronic heart or lung disease, kidney disease, diabetes)
  • Concomitant aspirin therapy
  • Possible immunodeficiency
  • History of GBS
Measle, mumps, rubella (MMR)
  • History of anaphylaxis to gelatin or neomycin
  • Known immunodeficiency
  • Pregnancy
Varicella
  • History of anaphylaxis to gelatin or neomycin
  • Known immunodeficiency
  • Pregnancy
Inactivated poliovirus vaccine (IPV)
  • History of anaphylaxis to streptomycin, neomycin, or polymyxin B

* A vaccine should not be . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?
Click here for Adolescent Immunizations Correction Data Supplement


Rapid Responses:

Read all Rapid Responses

Some questions
Madhu Desiraju
Pediatrics in Review Online, 24 Jun 2009 [Full text]
Menactra vs Menomune
Marjorie Alpert
Pediatrics in Review Online, 24 Jun 2009 [Full text]
Menactra vs. Menomune
Sydney Sutherland
Pediatrics in Review Online, 7 Jul 2009 [Full text]
Menactra and Menomune
Lawrence F. Nazarian
Pediatrics in Review Online, 7 Jul 2009 [Full text]
Adolescent Immunization
kathleen kicsak
Pediatrics in Review Online, 3 Sep 2009 [Full text]
Menactra: adol immunizations
Kathryn S. Brigham, et al.
Pediatrics in Review Online, 3 Sep 2009 [Full text]



HOME HELP CONTACT US SUBSCRIPTIONS CME ARCHIVE SEARCH TABLE OF CONTENTS
Pediatrics  Pediatrics in Review
Copyright © 2009 by the American Academy of Pediatrics.